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Abstract
Hypoglycaemia is common in clinical practice for people with diabetes. 
However, the symptoms can vary between individuals and at different stages of 
their condition. Moreover, several factors influence symptoms experienced by 
people with diabetes, and many are amenable to intervention. Symptoms are 
commonly neuroglycopenic or neurogenic in aetiology, and these lead to differ-
ent clusters of symptoms. Certain patient groups such as the elderly and pregnant 
women are particularly susceptible to hypoglycaemia. In this chapter, we describe 
the physiology and pathophysiology behind the symptoms of hypoglycaemia, with 
reference to current knowledge from neuroimaging studies, and outline potential 
interventions to modify or restore hypoglycaemia symptoms.
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1. Introduction
Hypoglycaemia is common in clinical practice with up to 45% of people with 
type 1 diabetes mellitus (T1DM) experiencing mild to moderate hypoglycaemia 
and 6% experiencing severe hypoglycaemia [1]. The average individual with type 
1 diabetes experiences two symptomatic hypoglycaemic episodes a week, and the 
prevalence of severe hypoglycaemia can be up to 30–40% [2].
The signs and symptoms of hypoglycaemia however can be variable and can 
change over time. In this chapter, we discuss the presentations of hypoglycaemia 
and the underlying pathophysiology.
2. Definition of hypoglycaemia
This has been a controversial area for many years, and only recently, a consensus 
has been developed. Normal blood glucose levels can range between 3.5 mmol/l 
(63 mg/dl) and 7.0 mmol/l (126 mg/dl), but individuals can develop lower val-
ues physiologically during fasting or starvation. Blood glucose levels less than 
3.0 mmol/l (54 mg/dl) are associated with poorer clinical outcomes.
The International Study Group suggests that a level of <3.0 mmol/l (54 mg/dl) 
be defined as denoting serious clinically important hypoglycaemia, whether that 
level is associated with symptoms or not, and that incidences of hypoglycaemia 
within that range be reported during clinical trials and in clinical practice [3].
The statement outlines proposed glucose levels to define severe hypoglycaemia as:
• Level 1: a glucose alert value of 3.9 mmol/l (70 mg/dl) or less. This need not be 
reported routinely in clinical studies, although this would depend upon the 
purpose of the study.
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• Level 2: a glucose level of <3.0 mmol/l (<54 mg/dl) is sufficiently low to 
indicate serious, clinically important hypoglycaemia.
• Level 3: severe hypoglycaemia, as defined by the American Diabetes Association, 
denotes severe cognitive impairment requiring external assistance for recovery.
2.1 Symptoms
The most frequently reported symptoms during hypoglycaemia in diabetes 
are sweating, trembling, inability to concentrate, weakness, hunger and blurred 
vision [4].
Generally, symptoms are divided into two groups:
a. Neuroglycopenic symptoms caused by brain glucose deprivation:
• Cognitive impairment (altered perception, poor concentration, slow/hesi-
tant speech, slow decision-making).
• Behavioural changes (irritation, frustration, refusal to help).
• Psychomotor abnormalities (incoordination, unsteadiness, weakness).
• Seizure/coma.
• Permanent neurological damage if prolonged severe hypoglycaemia.
b. Neurogenic symptoms caused by the sympathoadrenal response:
• Adrenergic (palpitations, tremulousness, anxiety, arousal, skin pallor/flush-
ing or blotchy rashes, tingling around the mouth/lips).
• Cholinergic (sweating, hunger, paresthesia) [5].
To try and understand why the above symptoms are present, or not present, we 
describe physiological and pathophysiological response to hypoglycaemia in people 
with diabetes.
Glucose is the fuel for the most of the body functions including cerebral 
function. The brain is not able to synthesize glucose and therefore is critically 
dependent on a continuous glucose supply from the circulation (20% of circulated 
glucose).
Glucose is transported into the brain across the blood–brain barrier by the glu-
cose transporter protein GLUT-1, and antecedent hypoglycaemia causes upregula-
tion of this transporter [6]. If however the glucose level falls quickly to critically low 
levels, then despite the upregulation of the transporter, the supply is not adequate, 
and it may lead to impairment of brain function.
2.2 Physiological response to hypoglycaemia
Normal body physiology (without diabetes) has a sequence of responses to 
handle hypoglycaemia.
The first response is to decrease insulin production from the β-cells and 
increase the glucose counter-regulatory (plasma glucose raising) hormones: 
glucagon and adrenaline. Glucagon and adrenaline are the principle hormones 
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to protect against acute hypoglycaemia by stimulating gluconeogenesis. Other 
hormones, cortisol and growth hormone play a less important role during hypo-
glycaemia. However deficiencies of these hormones can lead directly or exacer-
bate hypoglycaemia (i.e. Addison’s disease, hypopituitarism). As plasma glucose 
concentration progressively falls, the increasing sympathoadrenal (sympathetic 
and adrenomedullary) response leads to neurogenic symptoms. These symptoms 
cause awareness of hypoglycaemia that prompts behavioural defense of ingestion 
of carbohydrates (hunger) [7, 8].
2.3 Pathophysiological response to hypoglycaemia
However, in people with type 1 or type 2 diabetes mellitus (T2DM), the above 
defense mechanisms may be compromised due to:
Relative or absolute therapeutic hyperinsulinemia may lead to hypoglycaemia 
without intervention. The physiological defense mechanism of downregulation of 
insulin secretion may be impaired due to β-cell failure.
β-cell failure is also associated with the loss of an appropriate increase in circu-
lating glucagon [7–9]. In addition, the increase in circulating adrenalin is attenuated 
[7, 10]. Absent insulin/glucagon responses and attenuated epinephrine responses 
contribute to the clinical syndrome of defective glucose counter-regulation [7, 8, 
10]. As a consequence of losing the physiological control of glucose homeostasis, 
the body will develop neuroglycopenic and neurogenic symptoms as already listed 
above. The glucose level at which cognitive function declines is subject to substan-
tial variation (from levels between 3 and 4 mmol/l (54–72 mg/dl), whereas others 
continue to seemingly function with levels below 2.5 mmol/l (45 mg/dl). Almost all 
domains of cognitive function are potentially at risk during acute hypoglycaemia, 
with complex tasks being affected earlier than simple tasks [11].
2.4 Hypoglycaemic unawareness
The attenuated sympathoadrenal response is responsible for the reduced 
neurogenic symptom responses, well known contributing to the syndrome of 
hypoglycaemic unawareness [7, 8]. The patient has less time or no time between 
the onset of symptoms and the development of severe neuroglycopenia (impaired 
awareness/unawareness). Hypoglycaemic unawareness prevents patients from 
taking corrective action by eating which can potentially lead to seizure/coma and 
permanent neurological damage, if prolonged and severe. Thus, for many T1DM 
patients, the immediate fear of hypoglycaemia exceeds the fear of long-term diabe-
tes complications [12, 13]. Figure 1 is a diagrammatic summary of the physiological 
response to hypoglycaemia as well as the alterations in diabetes and hypoglycaemic 
unawareness.
In addition, certain drugs and alcohol may impair a patient’s perception of these 
symptoms. Beta-blockers may diminish the effect of adrenaline, potentially leading 
to reduced adrenergic warning symptoms (i.e. tremor, palpitations). Beta-blockers 
are not contraindicated in diabetes, but they should be considered when dealing 
with recurrent hypoglycaemia or hypoglycaemic unawareness. Other factors that 
can modify physical symptoms of hypoglycaemia are listed in Table 1. Nocturnal 
hypoglycaemia that can affect a significant percentage of patients and can be 
unrecognized is a contributing factor to hypoglycaemic unawareness.
The syndrome of defective glucose counter-regulation and hypoglycaemic 
unawareness usually develops early in T1DM and later in T2DM, due to differ-
ing rates of progressive beta-cell failure and also due to insulin or sulphonylurea 
medications often being started later.
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2.5 Hypoglycaemia-associated autonomic failure (HAAF)
HAAF is a dynamic functional disorder that includes several episodes of recent 
antecedent hypoglycaemia, combined with previous exercise or sleep, and causes 
defective glucose counter-regulation and hypoglycaemic unawareness. Late 
post-exercise hypoglycaemia occurs 6–15 h after strenuous exercise and is often 
nocturnal [14, 15]. Sleep-related HAAF is the result of further attenuation of the 
sympathoadrenal response to hypoglycaemia during sleep [16–18]. Subsequently, 
a vicious cycle of recurrent iatrogenic hypoglycaemia may occur. HAAF is distinct 
from the autonomic neuropathy. However, HAAF is more prominent in people with 
diabetic autonomic neuropathy [19, 20].
2.6 Symptoms in different groups
2.6.1 Children
Symptoms in children differ from those in adults. Children have a more vigorous 
catecholamine response to hypoglycaemia than adults. Behavioural changes such as 
irritability, stubbornness, quietness and tantrums may be the primary features of 
low blood glucose in children [21].
2.6.2 Elderly
This age group may have a more limited perception of autonomic symptoms of 
hypoglycaemia, which they report as lower intensity than young people. Therefore, 
older people are at greater risk of developing neuroglycopenia, as the warning symp-
toms do not always precede the development of cognitive dysfunction [22]. This may 
reduce the opportunity to take appropriate treatment before developing disabling 
confusion and neuroglycopenia. It is worth mentioning that the frequency of hypogly-
caemia in this group is probably underestimated. This is partly because of inadequate 
Figure 1. 
A schematic diagram describing the physiological response to hypoglycaemia.
1. Posture (the intensity of autonomic symptoms is greater in erect position compared to supine position)
2. Medications—toxins
• Impairing ability to perceive and interpret symptoms (i.e. hypnotic medications, alcohol, 
beta-blockers)
• Magnitude of symptomatic response (i.e. caffeine)
Table 1. 
Factors that alter hypoglycaemic symptoms.
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education in elderly or their relatives, and also frequently hypoglycaemic events are 
misinterpreted as TIAs, vertebrobasilar insufficiency and vasovagal attacks [23].
2.6.3 Pregnancy
It has been suggested that the intensity of the warning symptoms may be 
blunted during pregnancy [24, 25]. Of course this is very difficult to be study due 
to the ethical constraints surrounding the deliberate induction of experimental 
hypoglycaemia in early pregnancy. Considering that during pregnancy, women aim 
for stricter glycemic control, it is very difficult to distinguish whether the symp-
tomatology is a true alteration in the symptomatic response or the result of tight 
glycemic control and increased antecedent hypoglycaemia.
2.7 Functional and metabolic studies during hypoglycaemia
Recurrent hypoglycaemia which impairs awareness and the subsequent brain 
adaption is of scientific interest but incompletely understood. Several studies have 
been performed in order to understand brain network function during declining 
glucose levels.
Studies have shown significant EEG changes in euglycemia and hypoglycaemia 
during day and night in children with T1DM (20). Various neuroimaging techniques 
have been employed to study brain glucose metabolism including positron emission 
tomography (PET), magnetic resonance spectroscopy (MRS), functional magnetic 
resonance imaging (fMRI) and arterial spin labelling (ASL) [26].
Studies that have employed the above techniques have shown that cerebral 
glucose metabolism appears to be largely maintained during moderate hypoglycae-
mia. However, recurrent hypoglycaemia may initiate cerebral adaptions at many 
different levels. There is interference with the accurate detection of hypoglycaemia, 
probably occurring at the level of the ventromedial hypothalamus. Brain areas that 
control appetite and induce fear and anxiety may not become activated during 
hypoglycaemia. The underlying mechanisms, as to whether altered glucose uptake 
or neuronal activation or both in the hypothalamic area is responsible, remain 
unclear. Interestingly, patients with T1DM (particularly with impaired awareness) 
seem to be better able in maintaining brain glucose metabolism during hypoglycae-
mia than healthy controls [26].
2.8 Reversing hypoglycaemic unawareness
Avoidance of hypoglycaemic events enables people with unawareness to regain 
their symptoms when the glucose level is low. Often, preventing hypoglycaemia for 
2 weeks results in increased symptoms of a low blood glucose and a return to nearly 
normal symptoms after 3 months. There are different strategies that can be used in 
clinical practice to enable avoidance of hypoglycaemia. Some are listed below:
• Set blood sugar targets higher: this can lead to decreased frequency of 
hypoglycaemia.
• Education: educating patients in insulin adjustment is important. For example, 
a UK-based structured education program, Dose Adjustment for Normal eat-
ing (DAFNE), restores awareness in 43% of people with impaired awareness of 
hypoglycaemia [27]. Similarly, the HypoCOMPaSS trial showed that education 
around the prompt treatment of hypoglycaemia was as important as technolo-
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• Insulin pumps and continuous glucose sensors: insulin pump therapy, particularly 
sensor-augmented insulin pumps, has a role in reducing severe hypoglycaemia 
and restoring unawareness [29].
• Islet cell transplantation/pancreatic transplant: studies suggest immediate 
improvement of hypoglycaemic awareness in cases of functioning islet trans-
plantation [30]. Reversal of hypoglycaemia-associated autonomic failure is 
responsible for the long-term maintenance of hypoglycaemic awareness that 
returns after islet cell/pancreas transplantation [31].
3. Conclusions
Hypoglycaemia symptoms are variable and usually arise from impairment in 
counter-regulatory hormone or sympathoadrenal responses. Certain patient groups 
such as children, the elderly and pregnant women may be particularly vulnerable. A 
degree of hypoglycaemic unawareness is often a consequence of recurrent hypogly-
caemia and can be challenging to manage. Various strategies including education, 
technology and islet/pancreas transplants may all be useful.
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